Cancer vaccine candidates produced by domestic pharmaceutical and biotech companies are now one step closer to conquering intractable cancers, demonstrating effect in clinical trials. DXVX's cancer vaccine candidate has shown an effect on ovarian cancer and lung cancer, and Aston Science has entered Phase II clinical trials for gastric cancer to confirm its candidate drug’s commercialization potential. Hanmi Pharmaceutical is also planning to start clinical trials of a messenger ribonucleic acid (mRNA) cancer vaccine.

According to industry sources the 15th, OVM-200, a cancer vaccine candidate being developed by Oxford Vacmedix in the UK, has shown efficacy recently. Oxford Vacmedix is a spinof